Investors and Partners

Q-Sera’s technology is based on intellectual property from The University of Queensland (UQ) Centre for Clinical Research, which was identified and developed by UniQuest, the main commercialisation company of The University of Queensland.

About UniQuest

UniQuest is the main commercialisation company of the University of Queensland, specialising in the commercialisation of intellectual property, research outcomes and expertise. UniQuest has a 30 year track record and was responsible for the commercialisation of the HPV vaccine Gardasil®, the Triple P Positive Parenting Program, the image correction technology which is used in two-thirds of the world’s MRI machines, and Spinifex Pty Ltd, one of Australia’s largest biotech acquisitions. To learn more, visit www.uniquest.com.au.

Q-Sera has the support of leading Australian Investors, Uniseed and the Medical Research Commercialisation Fund (MRCF).

About Uniseed

Uniseed is a venture fund operating at the Universities of Melbourne, Queensland, New South Wales and Sydney, as well as the CSIRO. Uniseed’s mandate is to facilitate the commercialisation of research partner-generated intellectual property by targeting investment in highly promising technologies. Uniseed helps researchers from its partner research organisations to turn their ideas into products and services and to support innovations that solve market problems and create a positive impact for the community. Uniseed’s investments cover a range of technology sectors and to date, the fund has exited four investments through trade sales and one investment through asset sale. A number of companies in Uniseed’s investment portfolio also have products on the market, or are collaborating with leading global companies in their respective fields. For more information, go to www.uniseed.com

About The Medical Research Commercialisation Fund (MRCF)

The MRCF Collaboration, managed by Brandon Capital Partners, brings together over 50 of Australia’s leading medical research institutes and research hospitals in an innovative investment collaboration. The MRCF provides dedicated investment funding to support the commercialisation of early-stage medical research discoveries that originate from its members.

AU$ 200m MRCF3 fund launched in 2015 is supported by AustralianSuper, StatewideSuper, HESTA and HOSTPLUS industry superannuation funds. The MRCF’s first two funds, the MRCF Trust and MRCF IIF LP, totalling AU$ 51m were established in 2007 and 2011 and were supported by AustralianSuper, StatewideSuper and the Australian Government through its Innovation Investment Fund (IIF) program. The MRCF acknowledges support from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.

www.mrcf.com.au